SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, inclusive (the “Class Period”), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.), the DexCom class action lawsuit charges DexCom and certain of DexCom’s top executives with violations of the Securitie ...

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) between January 8, 2024 to July 25, 2024, both dates inclusive. You are hereby notified that the class action lawsuit Charlene Alonzo v. DexCom, Inc., et al. (Case No. 3:24-cv-01485 has been commenced in the United States District Court for the Southern District of C ...

RADNOR, Pa., Aug. 21, 2024 /PRNewswire/ -- law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) ("DexCom").On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. In addressing the results, DexCom stated that the comp ...

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...

These companies' growth paths should only be briefly interrupted by headwinds.The stock market remains one of the best ways to grow capital over time. And although having millions in the bank might help, a more accessible -- and perfectly sensible -- strategy is to invest relatively small sums regularly. Even $200 can go a long way, provided it's invested in quality corporations that can deliver excellent returns over the long run.There are many such companies on the market. Let's consider two examples wort ...

Look beyond share price at the business behind the stock, and you might find there's more for investors to consider.If you're looking for stocks on sale in the current market, despite the broader gains that major indices have clocked, many companies have responded in different ways. While a stock trading at a discount isn't in itself a reason to hit the buy button, great businesses are sometimes beaten down by investor sentiment and can present opportunities for the forward-thinking individual.Here are two ...

Group 1 - DexCom, Inc. is under investigation for potential violations of federal securities laws by Bleichmar Fonti & Auld LLP [1] - DexCom's stock experienced a significant decline of 38% following disappointing Q2 2024 earnings results and a reduction in full-year revenue guidance from $4.35 billion to a range of $4 billion to $4.05 billion [2] - The company attributed its poor performance to challenges in restructuring its sales force, while analysts speculated that the rise in popularity of GLP-1 weight loss drugs may have also impacted sales [2] Group 2 - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, having achieved notable recoveries in past cases [4] - The firm encourages DexCom investors to explore legal options, offering representation on a contingency fee basis, meaning no upfront costs for shareholders [3]

DexCom Inc. (DXCM) recently announced that its G7 Continuous Glucose Monitoring (CGM) System will be added to the Régie de l'assurance maladie du Québec (RAMQ) Public Prescription Drug Insurance Plan. Québec residents living with type 1 diabetes who meet the eligibility criteria are now likely to receive coverage for Dexcom G7.Québec becomes the latest province to offer public coverage for Dexcom G7, helping those living with type 1 diabetes access an innovative and effective management solution.More on the ...

Here's why DexCom should be on your radar after the company's share price plunged recently.Attractive investment opportunities can sometimes arise when investors react emotionally to short-term events. Some of these events revolve around the earnings season, when a company releases financial results that fall short of analysts' expectations. It can be a miss involving just a penny or two, but the stock will still get sold down savagely. Such was the case for DexCom (DXCM 3.30%), a manufacturer of continuous ...

NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...